Trials / Terminated
TerminatedNCT00931762
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assessed the safety and efficacy of Panobinostat as a single agent in the treatment of Primary Myelofibrosis, Post-Polycythemia Vera and Post-Essential Thrombocythemia. There were two cohorts - participants with JAK2 mutation and participants without JAK2 mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panobinostat | Panobinostat oral capsules |
Timeline
- Start date
- 2009-08-31
- Primary completion
- 2011-08-29
- Completion
- 2011-08-29
- First posted
- 2009-07-02
- Last updated
- 2021-07-30
- Results posted
- 2021-07-30
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00931762. Inclusion in this directory is not an endorsement.